Discovery of Novel Multifunctional Molecules for Synergistic Theranostics Based on Vascular Normalization Targets

Tumor vascular abnormalities can reduce drug and oxygen delivery and induce tumor resistance. However, it has recently been found that a few antiangiogenic drugs can achieve significant efficacy when combined with chemoradiotherapy, which is contrary to the effect of antiangiogenic drugs in clearing blood vessels. The theory of vascular normalization, originating from clinical observations, has explained this paradox and has become a promising strategy to overcome the bottleneck of tumor treatment, but there is a lack of innovative drugs. Based on the previous identification of the novel vascular normalization target EphrinB2, a synergistic strategy, "vascular normalization─chemotherapy" was proposed. Based on the principle of twin drugs in drug design and the controlled release strategy, we found a new type of vascular normalization-chemotherapy twin drug based on the active molecule QDAU5, which showed good membrane permeability, strong stability, rapid toxic payload release characteristics, and strong inhibitory activity against colorectal tumors. The study further enriches the theory of vascular normalization and promotes its expansion into the field of new drug development.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-01-14
DOI
https://doi.org/10.1021/acs.molpharmaceut.5c01544
Primary Topic
Angiogenesis and VEGF in Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Novel Multifunctional Molecules for Synergistic Theranostics Based on Vascular Normalization Targets

Ye Li, Tingting Liu, Yangchao Wei, Lifeng Zhao et al.
Molecular Pharmaceutics
Angiogenesis and VEGF in Cancer
article

Discovery of Novel Multifunctional Molecules for Synergistic Theranostics Based on Vascular Normalization Targets

Ye Li, Tingting Liu, Yangchao Wei, Lifeng Zhao, Jie Zhang, Weihua Cheng
article en

Abstract

Tumor vascular abnormalities can reduce drug and oxygen delivery and induce tumor resistance. However, it has recently been found that a few antiangiogenic drugs can achieve significant efficacy when combined with chemoradiotherapy, which is contrary to the effect of antiangiogenic drugs in clearing blood vessels. The theory of vascular normalization, originating from clinical observations, has explained this paradox and has become a promising strategy to overcome the bottleneck of tumor treatment, but there is a lack of innovative drugs. Based on the previous identification of the novel vascular normalization target EphrinB2, a synergistic strategy, "vascular normalization─chemotherapy" was proposed. Based on the principle of twin drugs in drug design and the controlled release strategy, we found a new type of vascular normalization-chemotherapy twin drug based on the active molecule QDAU5, which showed good membrane permeability, strong stability, rapid toxic payload release characteristics, and strong inhibitory activity against colorectal tumors. The study further enriches the theory of vascular normalization and promotes its expansion into the field of new drug development.

Molecular PharmaceuticsVol. 23(2)
Pancreatic Cancer UK (GB), Baoji City Central Hospital (CN), Xi'an Jiaotong University (CN)
Good health and well-being
Openalex Percentile: Top 89%
Angiogenesis and VEGF in Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Discovery of Novel Multifunctional Molecules for Synergistic Theranostics Based on Vascular Normalization Targets — Ye Li, Tingting Liu, et al. · Molecular Pharmaceutics (2026) | TGRS Research Map | TGRS